 Genocea Biosciences Inc NASDAQ: GNCA has shared initial data from Phase 12a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at American Association for Cancer Research AACR show anti-tumor activity despite the. 